NCT01568294 is a Phase 1 clinical trial of pomalidomide in Multiple Myeloma, sponsored by Celgene.

Who is sponsoring NCT01568294?

NCT01568294 is sponsored by Celgene.

What drugs are being tested in NCT01568294?

Interventions in NCT01568294: pomalidomide.

What condition does NCT01568294 study?

NCT01568294 studies Multiple Myeloma.

Is NCT01568294 still recruiting?

NCT01568294 is currently completed. Last updated 12 November 2019.

Last reviewed 2019-11-12 · How we verify

NCT01568294

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Completed Phase 1 Last updated 12 November 2019

What this trial tests

Phase 1 trial testing pomalidomide in Multiple Myeloma in 12 participants. Completed in 8 July 2015.

Timeline

1 April 2012

Primary endpoint
8 July 2015

8 July 2015

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 April 2012
Primary completion	8 July 2015
Estimated completion	8 July 2015
Sites	8 locations across Japan

Drugs / interventions tested

pomalidomide — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Celgene — full company profile →

Who can join

20 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the tolerated dose of pomalidomide and also to evaluate the pharmacokinetics, safety and efficacy of pomalidomide in patients with refractory or relapsed and refractory multiple myeloma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.
Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, et al · · 2013 · cited 94× · PMID 24013664 · DOI 10.1038/bcj.2013.38
Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma.
Matsue K, Iwasaki H, Chou T, Tobinai K, et al · · 2015 · cited 11× · PMID 26292221 · DOI 10.1111/cas.12772

Verify or expand the search:

Other trials of pomalidomide

Trials testing the same drug.

NCT06508983 — A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in R · Phase 3 · recruiting
NCT05432414 — PVd Versus Vd in NDMM Patients With RI · Phase 2 · unknown
NCT04045795 — Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) · Phase 1 · completed
NCT03582033 — A Safety Study of SEA-BCMA in Patients With Multiple Myeloma · Phase 1 · terminated
NCT02659930 — Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma · Phase 1 · active not recruiting

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01568294 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 12 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01568294.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing